;
Home | News & Events

NEWS, OPINION AND EVENTS

Keep up to date with life at the Babraham Research Campus. Explore the latest news, opinion and events from the campus, our stakeholders, partners and the companies based here.

Latest News

22/11/19

Cambridge biotech luminaries deliver masterclass on hiring and investment

Our winning Accelerate@Babraham start-ups benefit from the experience of two of the most prominent biotech names in the Cambridge life science cluster - Dr Jane Osbourn and Dr Andy Richards.

Read more

Cambridge biotech luminaries deliver masterclass on hiring and investment

22/11/2019

Our winning Accelerate@Babraham start-ups benefit from the experience of two of the most prominent biotech names in the Cambridge life science cluster - Dr Jane Osbourn and Dr Andy Richards.

Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

18/11/2019

Bicycle Therapeutics today announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 2:40 p.m. GMT (9:40 a.m. ET) in London, England.

PredictImmune pleased to announce the appointment of James Clark as Chief Technology Officer

18/11/2019

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome James Clark as Chief Technology Officer.

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumours

18/11/2019

Bicycle Therapeutics today announced that the first patient has been dosed in the Phase I dose escalation of its Phase I/II study of BT5528, a BicycleToxin Conjugate (BTC) targeting tumour antigen EphA2, in patients with advanced solid tumours associated with EphA2 expression. 

PhoreMost and Sentinel extend cancer collaboration

18/11/2019

PhoreMost and Sentinel Oncology have expanded a collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.

Sphere Fluidics hits a fresh Peak with cell analysis collaboration

18/11/2019

Sphere Fluidics, which is commercialising single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation which supplies intelligent lab automation solutions, have announced a cell analysis collaboration.

The Babraham Research Campus accelerator programme attracts further sponsorship to support early-stage science ventures

11/11/2019

With the second wave of its ‘Accelerate@Babraham’ life sciences bio-incubator programme well underway, the Babraham Research Campus has confirmed additional financial and mentoring support for the initiative from Mundipharma.

Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update

07/11/2019

Bicycle Therapeutics today reported financial results for the third quarter ended September 30, 2019 and discussed recent corporate updates.

PredictImmune and the Crohn’s & Colitis Foundation announce start of jointly-sponsored study to validate PredictSURE IBD™

07/11/2019

PredictImmune today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.

Bicycle Therapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting

31/10/2019

Bicycle Therapeutics today announced that new preclinical data from BT7480, a potent tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), will be presented at the Society for Immunotherapy of Cancer’s (SITC) 2019 Annual Meeting.

PredictImmune appoints Steven S. Martin as non-executive director

05/11/2019

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Steven S. Martin to its board.

 

Bicycle Therapeutics Announces Appointment of Veronica Jordan, Ph.D., to Board of Directors

31/10/2019

Bicycle Therapeutics today announced the appointment of Veronica Jordan, Ph.D., to its Board of Directors, where she will serve as Chair of the Compensation Committee. 

Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer

29/10/2019

Bicycle Therapeutics today announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone. Dr. Crockett has more than 25 years of experience in global business development for biopharmaceutical companies.

PredictImmune announces a strategic agreement with Theradiag

29/10/2019

PredictImmune announces a strategic agreement with Theradiag for French speaking Europe to commercialise PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease.

Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute

22/10/2019

Bicycle Therapeutics today announced that it will collaborate with Oxford University’s Oxford Drug Discovery Institute (ODDI) to use Bicycle® technology for the development of novel therapeutics for dementia.

PredictImmune announces new strategic partnership to commercialise its PredictSURE IBD™ prognostic test

22/10/2019

PredictImmune today confirmed that it has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to commercialise and provide PredictImmune’s prognostic test for inflammatory bowel disease (IBD), PredictSURE IBD™, throughout North America.

Bridging the Innovation Gap with AI

18/10/2019

Chief Executive of Clinical and Strategic Partnerships at BenevolentAI Dr Jackie Hunter writes a piece for Pharma Boardroom on why the pharmaceutical industry has been slow to adopt artificial intelligence-based technologies and also makes a prediction for the industry’s future.

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

18/10/2019

Chipscreen Biosciences and Novogene recently announced a strategic partnership for companion diagnostics (CDx) development. 

Meet Ashok at EMNLP for an oral presentation about his latest paper co-authored with Sia Togia

18/10/2019

Meet Ashok, researcher at BenevolentAI, at EMNLP for an oral presentation about his latest paper co-authored with Sia Togia: Biomedical relation extraction with pre-trained language representations and minimal task-specific architecture.

Abzena Names Kimball Hall as Chief Operating Officer

18/10/2019

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team.

BioMed Realty announces first lettings at Babraham Research Campus in Cambridge

17/10/2019

Today, BioMed Realty, the leading provider of real estate solutions to the life science community, announced its two newly developed Babraham Research Buildings in Cambridge are more than 50% let or under offer, including leases to PetMedix Ltd and Mission Therapeutics Ltd.

Induction Day with Cambridge Life-Science Cluster Vanguards for Accelerate@Babraham 2019 Winners

04/10/2019

The Babraham Research Campus has welcomed the second group of start-ups to its Accelerate@Babraham competition programme with a day of networking and a stellar cast of guest speakers.

Mote Research secures an Innovate Smart Grant

01/10/2019

Mote Research is delighted to announce that it has secured an Innovate Smart Grant. This grant will fund a £0.5M project to further develop and test Mote’s therapeutic genome editing technology. 

Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress

30/09/2019

Bicycle Therapeutics today announced the presentation of updated data from a Phase I/IIa trial conducted in collaboration with Cancer Research UK and evaluating BT1718 in an unselected group of patients with advanced solid tumours.

Innovation Seminar: Bioassay Development and Immunogenicity Testing in a Regulated Environment

30/09/2019

This event is mainly targeting protein and antibody researchers, bioanalysis research scientists and research groups with an interest in precision medicine, translational oncology and biomarkers.

Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial at ESMO 2019 Annual Congress

24/09/2019

Bicycle Therapeutics plc today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evaluating the Company’s lead asset BT1718 in patients with advanced solid tumors will be presented at the European Society of Medical Oncology (ESMO) 2019 Annual Congress. 

Accelerate@Babraham attracts additional sponsorship to boost innovation in Cambridge life science cluster

23/09/2019

LifeArc joins AstraZeneca in providing funding towards the continued development of the Babraham Research Campus’ Accelerate@Babraham initiative.

Science awards shortlist highlights talent and achievements at the Babraham Research Campus

19/09/2019

Babraham-based companies prominent in biotech, life science and innovation categories.

PredictImmune announces new ‘framework agreement’ with Cambridge Enterprise

19/09/2019

The agreement will allow future expansion of original IP license to expand its commercial product pipeline; extending the benefits of prognostic testing to include systemic lupus erythematosus (SLE).

Babraham Research Campus companies represented in Cambridge Independent Science and Technology Awards shortlisting

13/09/2019

The shortlist represents a showcase of the enormous talent in the Cambridge region across sectors from biotech to cleantech, artificial intelligence to agritech including companies from Babraham Research Campus.

Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer

13/09/2019

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announces that Stewart Kay has been appointed as the Companys Chief Business Officer (CBO).

BenevolentAI announces Agreement with leading healthcare company to leverage BenevolentAI’s technology platform

13/09/2019

BenevolentAI today announced that it has signed a Framework Collaboration Agreement with Novartis Pharma AG (“Novartis”) to leverage BenevolentAI’s technology platform to interrogate clinical trial and experimental data.

Conferencing and Events team shortlisted for top industry award

05/09/2019

The Conferencing and Events team at the Babraham Research Campus is delighted to have made the shortlist for 2019’s miaList which honours the industry’s greatest talents.

What the Cambridge & Peterborough Local Industrial Strategy means for Life Sciences

21/08/2019

One Nucleus CEO Tony Jones examines what the Cambridge and Peterborough Local Industrial Strategy means for life sciences.

Benevolent AI‘s Dr Jackie Hunter discusses defining innovation

21/08/2019

Benevolent AI’s Dr Jackie Hunter (CE Clinical & Strategic Partnerships) debates the culture of innovation, how to define, approach and measure it in interview with IDEA Pharma.

PredictImmune appoints Tim Rea of BGF as non-executive director

20/08/2019

PredictImmune is delighted to welcome Tim Rea, an experienced entrepreneur and investor at BGF, to its board.

An Interview With Dr. Daniel Ives of Shift Bioscience

09/08/2019

Shift Bioscience is a company aiming to solve the problem of mitochondrial dysfunction, one of the hallmarks of aging, by repairing the aging mitochondria in our cells so that they work as if they were younger.

More than £16 million Innovate UK and private equity investment into companies confirmed

09/08/2019

More than £16 million Innovate UK and private equity investment into companies across the UK developing new precision medicine technologies has been confirmed including Closed Loop Medicine.

Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update

08/08/2019

Bicycle Therapeutics plc, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.

Bicycle Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

01/08/2019

Bicycle Therapeutics plc, today announced that management will present at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 at 1:30 p.m. EDT in Boston, MA.

Human Developmental Biology Initiative announced

31/07/2019

Institute researchers are part of a world-first research project that will unravel how human embryos develop in the first weeks and months after fertilisation, improving our understanding of fertility, birth defects and regenerative medicine.

RNA Epigenetics in Human Disease Conference

31/07/2019

STORM Therapeutics' RNA Epigenetics in Human Disease Conference will take place 17th-20th September.

Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda

31/07/2019

Crescendo Biologics Ltd (Crescendo) announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised a second option under its existing, multi-target collaboration and license agreement.

PredictImmune closes Series B funding round, raising £10M to further accelerate global commercial expansion and support expanding product pipeline

30/07/2019

PredictImmune today announced the completion of its Series B funding having raised £10M.

Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters

23/07/2019

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund. 

Closed Loop Medicine receives major InnovateUK grant award for hypertension clinical programme

23/07/2019

Closed Loop Medicine raises £1.3 million in research grant funding through the InnovateUK Innovation Accelerator, Longwall Ventures and IQ Capital.

Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

23/07/2019

Abzena announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). 

Start Codon strengthens senior team with key appointments

16/07/2019

Start Codon announced today two appointments to its senior team. Daniel Rooke has joined as Partner and Head of Operations, and Sakura Holloway as Partner and Head of Diligence.

RNA proximity sequencing reveals the spatial organisation of the transcriptome in the nucleus

16/07/2019

Sphere Fluidics are proud to be involved in study where Proximity RNA-seq was used to understand the spatial organisation of RNA molecules in the nucleus.

Studying our ageing immune system with help of Cambridge BioResource

16/07/2019

The study of how our immune system changes as we age has been aided by volunteers in the Cambridge BioResource.

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director

16/07/2019

PhoreMost today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director.

Kymab Appoints Catherine Moukheibir as Non-Executive Director

16/07/2019

Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, announces the appointment of Catherine Moukheibir as a Non-Executive Director.   

Wall Street warms to Bicycle history makers

09/07/2019

Therapeutics powerhouse Bicycle is a history-maker in the sphere of life sciences. It can justifiably claim to be the first company to be headquartered in Cambridge at the time of an IPO on the NASDAQ technology market in the US.

Validating innovative solutions in cell biology

09/07/2019

A case study from Aureliabio using Atelerix Ltd innovative technology for room temperature preservation of cells and tissues.

PhoreMost and inStem enter structural biology alliance

09/07/2019

PhoreMost today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.

The winning formula behind Cambridge’s Silicon Fen success story

05/07/2019

William Wallis, UK Correspondent at the FT explores how collaboration between academics and entrepreneurs over 30 years has transformed the Cambridge region.

A whole new therapeutic area is taking medical research by storm

05/07/2019

Babraham Research Campus based Storm Therapeutics is leading the development of the first treatments to target a new layer of genetic information encoded in the RNA.

Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial

01/07/2019

Bicycle Therapeutics today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME). 

STORM Therapeutics Appoints Dr John Haurum to the Board of Directors

27/06/2019

STORM Therapeutics today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

27/06/2019

Abzena announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO).

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech

27/06/2019

UK medical research charity LifeArc is to take a $30m equity stake in biotech company Kymab, and will access its antibody platform to further its drug discovery efforts.

PATIENTS SUGGESTION LEADS TO NEW BRITISH COMPANY DEVELOPING THE WORLD’S FIRST ‘HOME USE’ BLOOD POTASSIUM TEST KIT

26/06/2019

A fast, accurate and low-cost test for blood potassium levels, which can be used at home and has the potential to improve the safety, health and lifestyle of tens of millions of people worldwide, is being developed by Kalium Diagnostics.

PhoreMost unveils plans for Series B and fresh spin-outs

26/06/2019

PhoreMost is set for a transformative phase of expansion that will create a revolutionary drug discovery business capable of influencing new treatments across a range of disease areas and featuring some of the world’s most influential Pharma players.

F-star appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA

20/06/2019

F-star Therapeutics Ltd today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.

F-star appoints Dr Louis Kayitalire as Chief Medical Officer

12/06/2019

F-star today announces the appointment of Louis Kayitalire, MD, as Chief Medical Officer (CMO), which will be effective on 17 June 2019.

Magdalene Boat Club Signs Up High-Growth Local Drug Developer RxCelerate as Headline Sponsor on a Five-Year Deal

12/06/2019

Magdalene Boat Club announced today that it had signed a sponsorship agreement with RxCelerate.

Sphere Fluidics closes a $4.8 million USD (£3.7 million) Funding Round

12/06/2019

Sphere Fluidics announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment.

Qkine secures additional £550K funding

03/06/2019

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

High-speed drama for Accelerate@Babraham pitches

28/05/2019

The second Accelerate@Babraham start-up competition final at the Babraham Research Campus proved even more full-throttle than the first.

Bicycle Therapeutics Announces Pricing of Initial Public Offering

23/05/2019

Bicycle Therapeutics, who are pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the pricing of its initial public offering in the United States.

STORM Therapeutics extends Series A to GBP 30M (USD 38.43M) with new investor, Seroba Life Sciences

22/05/2019

STORM Therapeutics today announced that it has raised an additional £14 million bringing the total Series A financing to £30 million.

ManChem funding roundup

22/05/2019

Atelerix Ltd, creator of an innovative cell encapsulation technology, has closed a second round of funding of £700,000 (US$893,000) to accelerate the development of its cell transport products to market.

Accelerate@Babraham Start-up Competition 2019: Winners Announced

21/05/2019

Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and an extended programme of mentoring and support.

Babraham Research Campus ready for pitching bonanza

13/05/2019

The Campus is going to be busy on Wednesday (May 15), with the one-day Babraham Investor Conference (BIC) immediately followed by the Accelerate@Babraham pitches, which gives five organisations the chance to work at Babraham for five months.

Bicycle Therapeutics Strengthens Clinical Team to Advance Expanding Pipeline

09/05/2019

Bicycle Therapeutics today announced two senior appointments to facilitate its expanding and advancing clinical pipeline.

Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund

07/05/2019

Bicycle Therapeutics today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases.

AstraZeneca and BenevolentAI team up to fight chronic kidney disease and idiopathic pulmonary fibrosis

07/05/2019

A long-term collaboration between AstraZeneca and BenevolentAI will bring the power of artificial intelligence and machine learning to bear in the hunt for new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

01/05/2019

Mission Therapeutics today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect.

PolyProx Therapeutics raises £3.4m seed financing to validate novel class of drugs to treat cancer

30/04/2019

PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.

The Medicine Maker 2019 Power List

25/04/2019

Benevolent AI‘s Prof Jackie Hunter, Director, featured as a Champion of Change in The Medicine Maker 2019 Power List.

The academic founders' conundrum

25/04/2019

Tony Kouzarides spoke to BioCentury about co-founding Storm Therapeutics and how academics connect with the biotech industry to build companies.

Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumor-targeted Bispecific Bicycles at Peptides Congress

24/04/2019

Bicycle Therapeutics announced today that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will present at the 6th Annual Peptides Congress in London.

Start Codon founded in Cambridge, UK, to deliver premier life science and healthcare business acceleration program

23/04/2019

Start Codon has been launched with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.

Dutch specialist buys Cambridge science building

08/04/2019

Dutch property investor and developer Kadans Science Partner has taken its first step into the Cambridge and UK life science market by acquiring a major building on the Babraham Research Campus from Imperial College ThinkSpace.

Kymab appoints Simon Sturge as Chief Executive Officer

08/04/2019

Kymab today announced the appointment of Simon Sturge as its new CEO, effective May 1, 2019. Simon succeeds David Chiswell, who remains a scientific adviser to the Company.

Theodora Harold to be appointed new CEO at Crescendo Biologics

04/04/2019

Crescendo Biologics Ltd (Crescendo) today announces that Theodora Harold will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.

Bicycle Therapeutics to Present at ELRIG’s Research & Innovation 2019 Conference

02/04/2019

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that Paul Beswick, Ph.D., Bicycle’s Director of UK Chemistry and IP, will present at the Research & Innovation 2019 conference.

PredictImmune’s first prognostic test for IBD, PredictSURE IBD™, launches in the UK and Ireland

02/04/2019

PredictImmune today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.

Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

01/04/2019

Dr. Smith will assume responsibility for leading Artios's overall preclinical and clinical development strategy, regulatory, and medical activities.

Bicycle Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting

29/03/2019

Bicycle Therapeutics announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.

NICE issues Medtech Innovation Briefing on PredictSURE IBD™ for inflammatory bowel disease prognosis

28/03/2019

PredictImmune today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.

NEMESIS BIOSCIENCE WINS INNOVATE UK SBRI FUNDING AWARD

27/03/2019

Nemesis Bioscience has been successful in winning a £414, 000 award granted by the UK’s innovation agency, Innovate UK.

Rob Treanor joins Sphere Fluidics as Director of Operations and Andrew Campbell as Director of Finance

26/03/2019

Sphere Fluidics announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites.

 

Investors invited to discover the next big thing in life science and med-tech

25/03/2019

Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.

ImmBio signs deal with CNBG in China to develop pneumococcal disease vaccine

24/03/2019

ImmBio’s PnuBioVax vaccine aims to be the first vaccine targeting all S. pneumoniae variants, and offers the potential to tackle the antibiotic resistance problem at its source.

Abzena Announces New Fully Integrated Developability and Optimization Service

21/03/2019

Abzena announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service.

PredictImmune wins Business Weekly Life Science Innovation (Product) award

21/03/2019

PredictImmune is delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.

NeoPhore appoints Dr John Haurum as Non-Executive Director

20/03/2019

NeoPhore Limited, a cancer
immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect.

Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman

18/03/2019

Bicycle Therapeutics announced today the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors.

Apply to present at the 2019 Babraham Investor Conference

18/03/2019

The Babraham Investor Conference (BIC) is back to bring together like-minded investors focussed on early-stage and scale-up life science and med-tech opportunities.

PredictImmune announce formal entry of PredictSURE IBD™ into the NICE Diagnostic Assessment Programme

12/03/2019

The DAP evaluates new, cutting-edge medical diagnostic technologies, producing guidance to help people working in the NHS make efficient, cost-effective and consistent decisions about adopting new products.

Applications now open for the second Accelerate@Babraham life-science start-up competition

06/03/2019

The annual competition gives up to five ventures the opportunity to win access to facilities, and take part in a fast-paced programme of support, led by a hand-picked group of experienced academic and commercial life science experts.

Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumors, at World ADC 2019

05/03/2019

Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London. 

PredictImmune announce issuance of new patent in the US in support of commercialisation

26/02/2019

PredictImmune today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property relating to methods for predicting autoimmune disease risk.

Bicycle Therapeutics Strengthens Executive Team with Key Changes

20/02/2019

Bicycle Therapeutics today announced several key changes to its executive team, including the appointment of Peter B. Leone as Chief Business Officer and the promotion of Lee Kalowski, Chief Financial Officer, to the role of U.S. President.

Babraham Bioscience Technologies announce new Board Member

18/02/2019

The Board of Babraham Bioscience Technologies (BBT) welcomes Dr Karen Lewis as Non-Executive Director.

Bicycle Therapeutics Awarded £496,000 (US $640,000) SBRI Contract to Address Antimicrobial Resistance in Humans

12/02/2019

Bicycle Therapeutics announces it has been awarded a contract from the Department of Health and Social Care as part of the Small Business Research Initiative.

Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

11/02/2019

In an exceptional career in Pharmaceutical R&D Professor Chopra has held a number of distinguished roles, and has now been appointed as Non-Executive Director of Artios Pharma.

Business Weekly New Year Honours 2019

17/01/2019

Business Weekly has announced its New Year Honours 2019. Find out where Babraham Research Campus was listed below.

Sphere Fluidics closes $2m (£1.5m) investment round

29/01/2019

Sphere Fluidics announced today that it has closed a $2 million (circa £1.5 million) investment round.

PredictImmune confirms Canadian patent grant

24/01/2019

PredictImmune today confirmed its latest patent grant in Canada.

PREDICTIMMUNE MAKES FURTHER STRIDES TOWARDS JANUARY LAUNCH OF PREDICTSURE IBD™, BY GAINING ISO 13485 MEDICAL DEVICES CERTIFICATION

18/12/2018

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced confirmation of its ISO 13485 certification.

Presentation day showcases success of Accelerate@Babraham start-up competition

23/12/2018

The first ever life science bio-incubator programme competition at the Babraham Research Campus, Accelerate@Babraham, has ended on a high for the competition winners with the promise of ongoing mentoring and an invitation to present at the renowned Babraham Investor Conference in 2019.

PredictImmune awarded Innovate UK grant to apply its biomarker-based technology towards the prediction of drug response in IBD

14/12/2018

PredictImmune, developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded a grant of £100,000 by Innovate UK, the UK’s innovation agency. 

PredictImmune’s first prognostic test, PredictSURE IBD™, set for UK and European launch having been awarded CE mark

11/12/2018

PredictImmune today announced CE IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification for its prognostic biomarker test for IBD, PredictSURE IBD- the first validated biomarker based prognostic test in inflammatory disease.

Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

07/12/2018

Mission Therapeutics has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect.

PredictImmune and the Crohn’s & Colitis Foundation announce a joint study to validate and prove efficacy of first prognostic test for IBD in the US market

04/12/2018

PredictImmune today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.

BICYCLE THERAPEUTICS TO PRESENT AT 30TH ANNUAL PIPER JAFFRAY HEALTHCARE CONFERENCE

27/11/2018

Bicycle Therapeutics announced today that management will present a company update at the 30th Annual Piper Jaffray Healthcare Conference.

BICYCLE THERAPEUTICS NAMED BEST NEW DRUG DEVELOPER AT 2018 WORLD ADC AWARDS

14/11/2018

Bicycle Therapeutics today announced that it has been recognized at the 2018 World ADC Awards, held during the World ADC Conference in San Diego, Calif., as Best New Drug Developer.

BICYCLE THERAPEUTICS’ FOUNDER SIR GREGORY WINTER TO DELIVER KEYNOTE ADDRESS AT THE 2018 PROTEIN AND ANTIBODY ENGINEERING (PEGS) SUMMIT EUROPE

13/11/2018

Additional company presentation will highlight preclinical research supporting the development of CD137 Bicycle® agonists as novel cancer immunotherapies.

BICYCLE THERAPEUTICS TO PRESENT AT JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE08

08/11/2018

Bicycle Therapeutics announced today that management will present a company update at the Jefferies 2018 London Healthcare Conference.

PREDICTIMMUNE ANNOUNCES NEW PATENT GRANTS AND ALLOWANCES ACROSS THE UK, EU AND CANADA

18/10/2018

PredictImmune announced today the granting of patents in the UK and Europe and Notice of Allowance in Canada relating to a method for predicting autoimmune disease risk.

ACCELERATE@BABRAHAM INTAKE LEARNS HOW TO WALK THROUGH WALLS

04/10/2018

A memorable induction for the first-ever Accelerate@Babraham competition winners cohort included masterclasses from two of Cambridge’s most spectacularly successful entrepreneurs and investors, Andy Richards and Jonathan Milner.

PredictImmune invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit

03/10/2018

PredictImmune announced today that it has been invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit in October 2018.

ACCELERATE@BABRAHAM ATTRACTS ADDITIONAL SUPPORT FROM TAYLOR VINTERS AND SILICON VALLEY BANK

10/09/2018

International law firm and technology focused banking group confirm support for Accelerate@Babraham’s inaugural programme.

ABZENA ACQUIRED BY ASTRO BIDCO LIMITED, A NEW COMPANY WHOLLY-OWNED BY THE WCAS FUND IN NEW YORK

17/08/2018

The Big Apple has taken another bite out of Cambridge UK biotech with a near-$44 million acquisition of Abzena by a newly-formed New York enterprise. 

ACCELERATE@BABRAHAM START-UP COMPETITION: WINNERS ANNOUNCED

13/07/2018

Five science start-ups have been awarded £20k and access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham.

PREDICTIMMUNE APPOINTS NEW CEO

02/07/2018

PredictImmune, a developer of pioneering prognostic products for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the appointment of Paul Kinnon as its new Chief Executive Officer.

HOW UK LIFE SCIENCES WILL TRANSFORM OUR LIVES

26/06/2018

Taylor Vinters is an international law firm supporting the businesses which drive the innovation economy, and the entrepreneurs and private wealth that underpin them.

SHIONOGI INVESTS IN NEMESIS TECHNOLOGY

19/06/2018

Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience. Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M.

THE BABRAHAM RESEARCH CAMPUS LAUNCHES START-UP COMPETITION FOR THE CHANCE TO ACCESS ITS LIFE SCIENCE BIO-INCUBATOR, ACCELERATE@BABRAHAM

29/05/2018

Life science start-ups are invited to apply for one of up to five prizes that include a cash prize and access to the Babraham Research Campus bio-incubator facilities and much more...

PREDICTIMMUNE JOIN THE BABRAHAM RESEARCH CAMPUS COMMUNITY

14/05/2018

Developer of pioneering tools for guiding treatment options in immune-mediated inflammatory diseases choose Babraham Research Campus as permanent base within the Cambridge Cluster.

PredictImmune secures £4.3m investment from Wellcome Trust to evaluate the clinical utility of its prognostic test in Crohn’s disease

30/04/2018

PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust.

IMPERIAL COLLEGE THINKSPACE FILLS SPACE AT THE BABRAHAM RESEARCH CAMPUS

17/04/2018

Imperial College ThinkSpace has welcomed two companies, Abzena plc and Bicycle Therapeutics Ltd, into its new 49,500 sqft building (Building 900) at the Babraham Research Campus near Cambridge.

THE BABRAHAM RESEARCH CAMPUS APPOINTS DR KAROLINA ZAPADKA TO LEAD ACCELERATE@BABRAHAM

19/03/2018

The Babraham Research Campus is delighted to announce the appointment of Dr Karolina Zapadka as Business Acceleration Manager for the Babraham Research Campus’ bio-incubator and life science accelerator, Accelerate@Babraham.

Registration now open for Babraham Investor Conference (BIC) 2018

Registration now open for Babraham Investor Conference (BIC) 2018

16/03/2018

Our highly successful annual Investor Conference for investors focusing on early-stage and scale-up life science and med-tech companies seeking Seed to Series C funding returns on the 22nd May.

DEREK JONES JOINS THE REGION'S LIFE SCIENCE & HEALTHCARE MEMBERSHIP ORGANISATION

DEREK JONES JOINS THE REGION'S LIFE SCIENCE & HEALTHCARE MEMBERSHIP ORGANISATION

07/03/2018

One Nucleus is delighted to announce the appointment of Derek Jones as a Non-Executive Director. Derek is Chief Executive of Babraham Bioscience Technologies Ltd (BBT), the organisation responsible for the development and management of the Babraham Research Campus.

New bio-incubator and life-science accelerator capability launches at the Babraham Research Campus

New bio-incubator and life-science accelerator capability launches at the Babraham Research Campus

25/01/2018

Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes (the ‘accelerator’).

Abzena takes on new facilities in Cambridge, UK and San Diego

Abzena takes on new facilities in Cambridge, UK and San Diego

05/01/2018

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.

BBT 'Technology Development Laboratory' (TDL) moves to Abzena

BBT 'Technology Development Laboratory' (TDL) moves to Abzena

05/01/2018

Abzena plc has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).

Bicycle Therapeutics Secures an Innovate UK Grant to Develop Next Generation Antibiotics

Bicycle Therapeutics Secures an Innovate UK Grant to Develop Next Generation Antibiotics

04/01/2018

Bicycle Therapeutics announced today that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.

BioMed@Babraham Partnership Launch

BioMed@Babraham Partnership Launch

20/12/2017

In October 2017, we were delighted to launch our partnership with BioMed Realty. This collaboration will see a new 108,000 square foot scale-up research space for growing bioscience-based companies built on site. Watch the launch video to find out more.

NOVOGENE ESTABLISHES FIRST EUROPEAN GENOMIC SEQUENCING CENTER AT THE BABRAHAM RESEARCH CAMPUS

21/05/2018

Novogene, a leading global provider of genomic services and solutions, today announced its first genomic sequencing center in Europe.

Biosceptre welcomes Tuspark S & T into its Series A fund raising round

Biosceptre welcomes Tuspark S & T into its Series A fund raising round

14/12/2017

Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7.

Bicycle Therapeutics & Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

Bicycle Therapeutics and Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

06/12/2017

Bicycle Therapeutics and Cancer Research UK today announced that their collaboration has secured a prestigious Scrip Award, winning 2017’s Best Partnership Alliance.

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore

15/12/2017

Sixth Element Capital LLP (6EC), a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund, announces a £3 million investment in NeoPhore Ltd, a spin out from Cambridge, UK based PhoreMost Ltd.

MRC spin out Bicycle Therapeutics announces partnership with AstraZeneca in $1bn deal

MRC spin out Bicycle Therapeutics announces partnership with AstraZeneca in $1bn deal

15/12/2017

In 2016, Bicycle Therapeutics - a MRC spin out company - entered into a collaboration with AstraZeneca potentially worth $1bn.

Crescendo Biologics Shortlisted for ‘Licensing Deal of The Year’

Crescendo Biologics Shortlisted for ‘Licensing Deal of The Year’

01/11/2017

Crescendo Biologics is pleased to announce that it has been shortlisted for ‘Licensing Deal of the Year’ at the Scrip Awards 2017.

Sphere Fluidics' Cyto-Mine wins major European Product Innovation award

Sphere Fluidics' Cyto-Mine wins major European Product Innovation award

01/11/2017

Sphere Fluidics’ proprietary Cyto-Mine® platform can perform multiple tasks in a single compact and portable system, reducing equipment costs and lab space.

Babraham Research Campus announces new life science development

Babraham Research Campus announces new life science development

26/10/2017

New project in grounds of the Babraham Research Campus will enhance Cambridge’s global position in life sciences community.

The only meeting checklist you’ll ever need

The only meeting checklist you’ll ever need

19/10/2017

The events team at Babraham Research Campus has many years of event management experience between them, here they share their knowledge to ensure your next meeting is a success.

How to use social media to make your next event memorable

How to use social media to make your next event really memorable

26/09/2017

We’ve all attended lots of events – training courses, team meetings, conferences – but some will stand out in your mind more than others. Why is this?

Solving the Problem of Scale Up - Babraham Panel Discussion

Solving the Problem of Scale Up - Babraham Panel Discussion

12/07/2017

See highlights of a panel discussion held in The Cambridge Building, which gathered senior key opinion leaders together to discuss the BioMed@Babraham development as well as the life science sector more broadly.

Babraham Research Campus Bennet Building

Babraham Research Campus Bennet Building

23/04/2017

The construction of the Bennet Building at the Babraham Research campus is discussed together with the role of the campus and BBSRC in innovation.

Cambridge Life Sciences

Cambridge Life Sciences

01/04/2017

Babraham Campus CEO Derek Jones leads us through a short history of monoclonal antibody research in the Cambridge life science cluster and asks what the next big thing will be in this area of exciting medical technology.

Bicycle Therapeutics Strengthens Senior Management Team

Bicycle Therapeutics Strengthens Senior Management Team

26/09/2017

Bicycle Therapeutics Strengthens Senior Management Team With Appointment of Maria Koehler, M.D., Ph.D., as Chief Medical Officer.

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

20/09/2017

Evelyn Warner, Editor of LaBiotech.eu, a leading digital media publisher covering the European Biotech industry interviews Derek Jones, Chief Executive of Babraham Bioscience Technologies (BBT) to talk about strategies for biotech startups.

How to find the perfect venue for your next meeting

How to find the perfect venue for your next meeting

20/09/2017

Behind every successful meeting, lies the perfect venue. This can often be overlooked while you’re focussing on the smaller details of the day. If you’re responsible for coordinating your organisation’s next conference, or seminar, choosing the right space will be crucial to it's success.

Support for - The UK Life Science Strategy - ‘Making the UK the best place for life sciences businesses to grow’

Support for - The UK Life Science Strategy - ‘Making the UK the best place for life sciences businesses to grow’

30/08/2017

As part of the UK’s £64B life sciences sector Babraham Bioscience Technologies, (BBT), welcomes the publication of Prof. Sir John Bell’s Life Science Industrial Strategy to the UK Government.

CEGX and NuGEN Technologies Sign Partnership Agreement

CEGX and NuGEN Technologies Sign Partnership Agreement

15/08/2017

Cambridge Epigenetix (CEGX) and NuGEN Technologies, today announced that they have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits.

Bicycle Therapeutics Expands Leadership Team

Bicycle Therapeutics Expands Leadership Team

01/08/2017

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the appointment of Lee Kalowski as Chief Financial Officer.

PRESS ENQUIRIES

We are keen to promote the work that we do, telling the story of the Babraham Research Campus and the organisations that are based here. If you are interested in running a story, using our images or films or want to discuss an interview or potential collaboration opportunity we would be very pleased to hear from you.  Please contact Sarah at Limewash to discuss your requirements

Sarah Brereton, Director, Limewash
01223 813 557, info@limewash.co.uk
www.limewash.co.uk

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;